Ludwig Cancer Research: Humanized Antibody Developed to Disrupt Fat Uptake in Tumor Immune Cells

A Ludwig Cancer Research study revealed that immune cells within tumors absorb fat in a way that can impede anti-cancer immune responses. Based on this discovery, researchers developed a humanized antibody that could potentially dismantle this barrier and act as a cancer immunotherapy. The research team, led by Ping-Chih Ho and Yi-Ru Yu of Ludwig Lausanne, along with Sheue-Fen Tzeng and Chin-Hsien Tsai, former post-doctoral researchers in the Ho lab who now lead their own labs at Taipei Medical University in Taiwan, identified a specific mechanism of fat uptake. This process acts as a metabolic checkpoint, hindering the immune system’s ability to fight the tumor. In response to this finding, the scientists engineered a humanized antibody. The goal of this antibody is to disrupt the identified fat uptake mechanism, potentially opening the door for more effective anti-cancer immune responses.

Newsflash | Powered by GeneOnline AI
Date: May 1, 2025

Related posts:

Tests on Sunglasses Show Deficiencies in Protection Against Ultraviolet Rays Revolutionary AI Tool Identifies Overlooked Brain Abnormalities in Epileptic Children Large-scale Study Pinpoints Key Interventions to Halt Hepatitis B Spread in Africa Breakthrough in Stroke Diagnosis: New AI Model Enhances Accuracy and Transparency

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後